Reproducible tendinitis-like symptoms related to statin therapy [1]

Journal of Clinical Rheumatology

Volumn 12, Issue 6, 2006, Pages 320-321

  Movahed, Mohammad Reza ^a   Samsamsharaiat, S Ahmad ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ACHILLES TENDON; ADULT; AGED; ANAMNESIS; CASE REPORT; DELTOID MUSCLE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; MALE; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RECURRENT DISEASE; SEROLOGY; SYMPTOMATOLOGY; TENDINITIS;

ADULT; AGED; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; MALE; SIMVASTATIN; TENDINOPATHY;

EID: 33845485270     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000250239.01489.3a     Document Type: Letter

References (11)

1. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-2590.
2. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-295.
3. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J. 2004;147:956-965.
4. Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-569.
5. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005;57:23-34.
6. Chazerain P, Hayem G, Hamza S, et al. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine. 2001;68:430-433.
7. Falip S, Batllo M, Peyrière H, et al. Statins Induced Tendinopathies: Analysis of 37 Cases Reported in the French. Centre de Pharmacovigilance, CHU Lapeyronie, Montpellier; Soumission 2005 Abstract poster 209.
8. Franc S, Dejager S, Bruckert E, et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17:459-465.
9. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial. BMC Med. 2005;3:6.
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
11. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation. 2005;112:563-571.